S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
New CBOE “special perk” helps traders target income every weekend (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
New CBOE “special perk” helps traders target income every weekend (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
New CBOE “special perk” helps traders target income every weekend (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
New CBOE “special perk” helps traders target income every weekend (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver

Travere Therapeutics (TVTX) Stock Forecast & Price Target

$6.42
+0.14 (+2.23%)
(As of 12/1/2023 ET)
Compare
Today's Range
$5.99
▼
$6.44
50-Day Range
$5.44
▼
$8.98
52-Week Range
$5.25
▼
$23.18
Volume
1.04 million shs
Average Volume
1.68 million shs
Market Capitalization
$482.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.38
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media

Travere Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 15 Analyst Ratings

Analysts' Consensus Price Target

$18.38
186.36% Upside
High Forecast$35.00
Average Forecast$18.38
Low Forecast$7.00
TypeCurrent Forecast
12/2/22 to 12/2/23		1 Month Ago
11/2/22 to 11/2/23		3 Months Ago
9/3/22 to 9/3/23		1 Year Ago
12/2/21 to 12/2/22
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
9 Buy rating(s)
9 Buy rating(s)
5 Buy rating(s)
Hold
6 Hold rating(s)
5 Hold rating(s)
3 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$18.38$19.33$28.21$34.00
Predicted Upside186.36% Upside76.41% Upside49.30% Upside39.99% Upside
Get Travere Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter.


TVTX Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

TVTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Travere Therapeutics Stock vs. The Competition

TypeTravere TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.60
2.67
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside186.36% Upside646.50% Upside2,853.20% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/20/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageNeutral$7.00+19.66%
10/25/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetNeutral ➝ Neutral$19.00 ➝ $10.00+43.47%
9/29/2023Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingOutperform ➝ Outperform$12.00+30.58%
9/22/2023Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower Target$30.00 ➝ $14.00+89.19%
9/22/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy ➝ Buy$32.00 ➝ $18.00+135.60%
9/22/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy ➝ Buy$25.00 ➝ $18.00+135.60%
9/22/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy ➝ Buy$41.00 ➝ $27.00+253.40%
9/22/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOverweight ➝ Overweight$31.00 ➝ $12.00+57.07%
9/22/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeOverweight ➝ Equal Weight$24.00 ➝ $8.00+4.71%
9/21/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating		T. Lugo
Subscribe to MarketBeat All Access for the recommendation accuracy rating		DowngradeOutperform ➝ Market Perform
7/21/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageOverweight$26.00+66.35%
7/18/2023Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy$37.00 ➝ $35.00+120.54%
5/22/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageOutperform$30.00+82.37%
5/5/2023Bryan, Garnier & Co
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeSell ➝ Neutral
12/13/2022Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageHold$22.00+16.09%
(Data available from 12/2/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












TVTX Price Target - Frequently Asked Questions

What is Travere Therapeutics's consensus rating and price target?

According to the issued ratings of 15 analysts in the last year, the consensus rating for Travere Therapeutics stock is Moderate Buy based on the current 6 hold ratings and 9 buy ratings for TVTX. The average twelve-month price prediction for Travere Therapeutics is $18.38 with a high price target of $35.00 and a low price target of $7.00. Learn more on TVTX's analyst rating history.

Do Wall Street analysts like Travere Therapeutics more than its competitors?

Analysts like Travere Therapeutics less than other Medical companies. The consensus rating score for Travere Therapeutics is 2.60 while the average consensus rating score for medical companies is 2.67. Learn more on how TVTX compares to other companies.

Is Travere Therapeutics being downgraded by Wall Street analysts?

Over the previous 90 days, Travere Therapeutics's stock had 2 downgrades by analysts.

Does Travere Therapeutics's stock price have much upside?

According to analysts, Travere Therapeutics's stock has a predicted upside of 74.00% based on their 12-month stock forecasts.

What analysts cover Travere Therapeutics?

Travere Therapeutics has been rated by Bank of America, Barclays, Citigroup, Evercore ISI, Guggenheim, HC Wainwright, Piper Sandler, Wedbush, Wells Fargo & Company, and William Blair in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:TVTX) was last updated on 12/2/2023 by MarketBeat.com Staff

My Account -